


CURRICULUM VITAE**DONALD M. JENSEN, MD, FACP, FAASLD**

8 September 2016

PERSONAL DATA:

Citizen: United States
 Residence: Oak Park, IL
 Married: Donna Hanlon (Jensen), MD
 Children: Colin and Emily

ADDRESS:

810 N. Kenilworth Avenue
 Oak Park, IL 60302-1519

CONTACT INFORMATION:

Mobile: 312-543-0922
 Office: 312-942-8910
djensen110@gmail.com
 @DonaldJensenMD (Twitter)

CURRENT ACADEMIC APPOINTMENT:

Professor of Medicine
 Department of Internal Medicine
 Hepatology
 RUSH University Medical Center
 Chicago, IL

Formerly Director, Center for Liver Diseases (until 11/30/14)
 Section of Gastroenterology, Hepatology and Nutrition
 University of Chicago Medicine
 5841 S. Maryland
 Chicago, IL 60637

EDUCATION:

1964-1968	University of Illinois Urbana, Illinois	B.S.
1968-1972	University of Illinois College of Medicine Chicago, Illinois	M.D.

RESIDENCY:

1972-1973	Medical Internship Presbyterian-St. Luke's Hospital; Chicago, Illinois
1973-1975	Internal Medicine Residency Rush-Presbyterian-St. Luke's Medical Center Chicago, Illinois
1975-1976	Chief Medical Resident Rush-Presbyterian-St. Luke's Medical Center Chicago, Illinois

FELLOWSHIPS:

- 1975-1976 Gastroenterology/Hepatology Fellowship
Section of Digestive Diseases
Rush-Presbyterian-St. Luke's Medical Center
Chicago, Illinois
- 1976- 1978 Hepatology Research Fellowship:
Liver Unit, King's College Hospital
Denmark Hill
London, England SE5 9RS
Director: Dr. Roger Williams

FACULTY APPOINTMENTS:

- 1978-1981 Instructor, Department of Medicine
Section of Digestive Diseases
Rush Presbyterian-St. Luke's Medical Center
Chicago, Illinois
- 1981-1988 Assistant Professor, Department of Medicine
Section of Digestive Diseases
Rush-Presbyterian-St. Luke's Medical Center
- 1988-1999 Associate Professor, Department of Medicine
Division of Digestive Diseases
Rush Presbyterian-St. Luke's Medical Center
Chicago, Illinois
- 1999- 2005 Professor of Medicine
The Richard B. Capps Endowed Professorship in Hepatology
Department of Internal Medicine
Rush University Medical Center
Chicago, Illinois
- 2005-2014 Professor of Medicine
Department of Medicine
University of Chicago
Chicago, Illinois
- 7/11/2016- Professor of Medicine
Department of Medicine
RUSH University Medical Center
Chicago, IL

MEDICAL LICENSES, BOARD CERTIFICATIONS, APPOINTMENTS:

- 1981 Gastroenterology Subspecialty Board Examination #53439 (11/10/81)
- 1975 American Board of Internal Medicine #53439 (6-18-75)
- 1974 State of Illinois License No. 36-048965
- 1973 National Board of Medical Examiners (#122072)
- 1995-05 UNOS Primary Liver Transplant Physician – Rush Medical Center
- 2005-06 UNOS Primary Liver Transplant Physician – University of Chicago

MEDICAL SCHOOL TEACHING

- 1978-1980 Physical Diagnosis for Rush medical students (M-2)
- 1978-2002 Gastroenterology Pathophysiology Course for M-2
Lecturer: 1979-2004
Workshop facilitator: 1978-2001
- 1987- 1998 Alternative Curriculum *Hepatitis* facilitator, M-2 (1990-1998)
- 2006-2007 Medical Biology 307, Clinical Pathophysiology Course, Liver Diseases
Section, Pritzker School of Medicine, Clinical Lab Preceptor

POSTGRADUATE TEACHING

- 1978-2014 Hepatology inpatient teaching service (3-6 months yearly)
1980-1995 Rush Internal Medicine Resident Board Review for *Hepatology*
1983-1996 Hines VA Internal Medicine Annual Board Review Course for *Hepatology*
1979-1998 The National Centers for Advanced Medical Education, Annual Gastroenterology Subspecialty Review Course lecture: *Hepatitis*
1994-1998 The National Center for Advanced Medical Education, Annual Family Medicine Review Course lecture: *Hepatitis and Gallstone Disease*
1989-1996 Problems in Gastroenterology, an annual six day, CME-approved review course for gastroenterologists, sponsored by Rush
1994-2001 Hepatitis Preceptor Programs, sponsored by Schering-Plough; Roche; Amgen

INTERNATIONAL LECTURES AND PRESENTATIONS (2012-2016)

- 2016 King's College Hospital Liver Unit 50 Year Celebration Symposium; Featured speaker
2015 Hepatitis C Symposium: 6th Expert Meeting on the Management of Patients with HCV Infection, Baveno, Italy, September 17-18, 2015: *Updated results of TARGET and TRIO studies. Focus on both compensated and decompensated cirrhosis with or without failure to first generation PIs*
2015 Hepatitis C Symposium, The Kirby Institute, University of New South Wales, Australia, September 10: *How will high-priced new agents translate to disease eradication?*
2015: EASL Plenary, Vienna; April 22: *Are Hepatitis C Medications Too Expensive?*
2015 Virology Meeting Point; Lisbon, Portugal: *Results in clinical trials are mirrored in clinical practice, even in cirrhotic patients*
2015 Paris Hepatitis Conference; Paris, France; *DAA and interferon-based therapies*
2014 Mongolia *Hepatology Update*; Ulanbatoor, Mongolia; December 2014: *Updates on Hepatitis C and Hepatitis B*
2014 Taiwan Digestive Disease Week: *Update on Hepatitis C*; October 2014
2013 HepDART; Hawaii: *Off Label Combinations of Newly Approved HCV Oral Therapies*
2013 Italian Association of Liver Disease; Baveno, IT: *Future Therapies of HCV*
2013 Israeli Association for the Study of Liver Disease; Eilat, Israel: *Future Interferon-free Therapies for Hepatitis C*
2013 Paris Hepatitis Conference; Paris, FR: Moderator: *New Hepatitis Therapies*
2012 EASL/AASLD Joint Conference on Hepatitis C; Prague, Czech Republic: *Debate: The Future Will be Interferon-free HCV Therapy*
2012 Paris Hepatitis Conference; Paris, FR: Lecture: *IL28B: Ten Years Too Late*

TEACHING AWARDS:

- 2014 **GI FELLOWS MENTOR AWARD**
Presented by the GI fellows at University of Chicago Medicine
2013 **GI FELLOWS TEACHING AWARD**
Section of Gastroenterology, Hepatology and Nutrition, University of Chicago Medicine
2008 **MEDICAL RESIDENT TEACHING AWARD**
Department of Medicine, University of Chicago Medical Center
1989 **DEPARTMENT OF MEDICINE TEACHING AND SERVICE AWARD**
Rush-Presbyterian-St. Luke's Medical Center
1980 **THE ATTENDING PHYSICIAN AWARD**
Department of Medicine; Rush-Presbyterian-St. Luke's Medical Center
1975 **THE FLICK FAMILY FUND AWARD** for Outstanding Medical Resident
Department of Medicine; Rush-Presbyterian-St. Luke's Medical Center
1974 **THE DEPARTMENT OF MEDICINE AWARD** for Outstanding Work As A Medical Resident; Rush-Presbyterian-St. Luke's Medical Center

OTHER AWARDS AND HONORS

- 2014 **Who's Who in the World** – Marquis Publishing 2014
2014 **Who's Who in America** – Marquis Publishing 2014
2014 **Chicago's Top Doctors** – Chicago Magazine, January 2014
2012 **Chicago's Top Docs** – Chicago Magazine, January, 2012
2011 **America's Top Doctors** – Castle-Connelly
2010 **Physician of the Year Award** – American Liver Foundation, Chicago
2010 **Chicago's Top Docs** – Chicago Magazine, January 2010
2010 **Who's Who in the World** – Marquis Publishing 2010
2009 **America's Top Doctors** – Castle-Connelly
2008 **Who's Who in America**, Marquis Publishing, 2008
2008 **Chicago's Top Docs**, Chicago Magazine, January, 2008
2008 **Americas Top Doctors**– Gastroenterology; Castle-Connelly Guide
2007 **Americas Top Doctors**– Gastroenterology; Castle-Connelly Guide
2006 **Chicago's Top Docs**; Chicago Magazine, January, 2006
2006 **Best Doctors in America** – Polling & Research Division, Inc.
2005 **America's Top Doctors** – Gastroenterology; Castle-Connelly Guide
2004 **America's Top Doctors** – Gastroenterology; Castle-Connelly Guide
2004 **Chicago's Top Docs**; Chicago Magazine, January 2004
2003 **America's Top Physicians – Hepatology**; The Consumers' Research Council of America
2001 **Physician Recognition Award**, American Liver Foundation, Chicago Chapter
1999 **Top Doctor, Chicago Metro Area**: Gastroenterology; Castle-Connelly
1998 **How to Find the Best Doctors** - Chicago Metro Area; Castle-Connelly



SOCIETIES LEADERSHIP:

- 2013- American Liver Foundation-Great Lakes Division
Board President
2013-2014 AASLD/IDSA co-chair for HCV Guidelines Development
2011-2013 American Association for the Study of Liver Diseases (AASLD):
Governing Board member: Treasurer
2011-2013 DDW Finance Committee member
2011-2013 DDW Governing Board
2005- Member, European Association for the Study of the Liver (EASL)
2003-2007 American Liver Foundation – National Board of Directors
2001- American Gastroenterology Association - member
1996-2005 Gift of Hope Subcommittee on Liver, Small Bowel and Pancreas Transplant
1984-1994 American Association of Clinical Chemistry
1983- American Liver Foundation,
Board of Directors 1994-2008
Medical Advisory Board Member 1994- ; Director 1998-2001
Chapter Vice President 2004-2006;
Chapter President 2006-2008; 2014-
1982-2000 American Federation for Clinical Research
1980-2000 American Association for the Advancement of Science
1978- American Association for The Study of Liver Disease (AASLD)
AASLD Practice Guideline Committee 1998-2001
AASLD Ad Hoc Web Site Review Committee 2000-04, 2007-08
AASLD Educational Materials Committee 2004-2007
Chairman 2006-2007
AASLD Educational Oversight Committee 2006-2009
AASLD Publications Committee 2007-2010
AASLD Fundraising Campaign 2007-2010
AASLD Abstract Reviewer 2004-06, 2008-2014

AASLD Finance Committee, Board liaison, 2011-2013
AASLD HCV Special Interest Group, 2012-
1978- American College of Physicians - Fellow 1983
1978-1996 Chicago Society of Gastroenterology – President 1993-1994

CONSULTATIVE POSITIONS

2015- Alliance for Patient Access (AfPA)
2015-2015 Gilead Scientific Advisory Board
2015-2015 Merck Scientific Advisory Board
2012-2013 Gilead Advisory Board
2012-2012 Biotica Advisory Board
2012-2012 Inhibitex Advisory Board
2009-2011 Pharmasset Hepatitis Advisory Board
2009-2013 Tibotec (Johnson & Johnson) Hepatitis Advisory Board
2008-2010 Human Genome Sciences, Hepatitis Advisory Board
2007-2008 Novartis Hepatitis Advisory Board
2006-2008 Astra-Zeneca Hepatitis Advisory Panel
2005-2006 Idenix Pharmaceuticals, Hepatitis Advisory Board
2004-2013 Bristol Myers Squibb, National Hepatitis Advisory Board
2004-2010 Globeimmune Pharmaceuticals Advisory Board
2003-2004 Amgen *Aranesp* Medical Advisory board
2001-2013 Boehringer-Ingelheim Hepatitis Medical Advisory Board
2001-2013 Roche Global Hepatitis Advisory Board
2002-2012 Vertex Hepatitis Advisory Group
2001-2002 Akros Pharmaceuticals Medical Advisory Board
2000-2002 Ribozyme Pharmaceuticals (RPI) Medical Advisory Board
1999-2001 Triangle Pharmaceuticals Hepatitis Advisory Board
1998-2013 Abbott Laboratories/Abbvie: Hepatitis Scientific Advisory Committee
1997-1999 Outcomes Task Force - FSGH
1997-1998 ADHF –Hepatitis Education Campaign
1996-2000 Steering Committee – Chicago Liver Group Investigators
1996-2000 Amgen Hepatitis National Medical Advisory Board
1995-2013 Roche/Genentech U.S. Hepatitis Medical Advisory Board
1995-2005 Pillsbury Resident Hospital Trust reviewer

DATA AND SAFETY MONITORING BOARDS/STUDY PANELS:

2015 NIH Hepatitis B Consortium Review Committee
2011-2013 Janssen/J&J/Centocor: CNTO1275PBC2001 Ustekinumab study
2007-2009 Chair, Globeimmune GI5005-02 Data Safety Monitoring Board
1996-2004 NIH Data/Safety Monitoring Board: TIPS vs DSRS Trial
2002-2002 Chairman, NIDDK ViraHepC laboratory review committee

HOSPITAL AND UNIVERSITY COMMITTEES:

2007-2014 U of C Gastroenterology Section: Fellow Promotion Committee
2005-2007 U of C, Physician's Working Group for Transplant Geography
2002-2005 Rush, Committee on Committees
1999-2001 Rush, Executive Committee
1995-1998 Rush, Committee on Educational Appraisal
1994-1997 Rush, Committee on Student Judiciary Review
1992-1995 Committee on Senior Faculty Appointments and Promotions (COSFAP)
1984-1986 Faculty Senate (RPSLMC)
1984-1989 Research Committee (Chairman), Department Of Medicine (RPSLMC)
1984-1989 University Committee on Research

1983-1987 Advisory Board, Office of Consolidated Laboratory Services (RPSLMC)
1981-1982 Committee on Committees (RPSLMC)
1980-1981 Faculty Senate (RPSLMC)
1975-1976 Faculty Council (RPSLMC)

Ad Hoc REVIEWER:

HEPATOLOGY
GASTROENTEROLOGY
NEW ENGLAND JOURNAL OF MEDICINE
ANNALS OF INTERNAL MEDICINE
AMERICAN JOURNAL OF GASTROENTEROLOGY
AMERICAN JOURNAL OF MEDICINE
ARCHIVES OF INTERNAL MEDICINE
JOURNAL OF VIRAL HEPATITIS
JOURNAL OF CLINICAL GASTROENTEROLOGY
DIGESTIVE DISEASES & SCIENCES
JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LANCET
LIVER INTERNATIONAL
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY
CLINICAL GASTROENTEROLOGY & HEPATOLOGY

EDITORSHIPS and EDITORIAL BOARDS:

Associate Editor (Viral Hepatitis): *Hepatology*, 2012-2014
Editorial Board: *Therapeutic Advances in Gastroenterology*, 2008-
Editorial Board, *Liver International*, 2008-
Editorial Board, *World J Gastro*, 2009-2011
Clinics in Liver Disease; **Cholestasis**, Editor, Feb 2008
Current Hepatitis Reports (Current Science, Inc.), 2002-
Clinics in Liver Disease; **Cholestasis**, Editor, Feb 2004
Clinics in Liver Disease; **Cholestasis**, Editor, August, 1999

PATENTS:

1985 United States Patent (No. 4,559,120) for DEVELOPMENT OF AN AGAROSE GEL ELECTROPHORESIS ASSAY FOR DETECTION OF AMYLASE ISOENZYMES.

VISITING PROFESSORSHIPS 2011-2014:

1. National Institutes of Health (NIH and NIDDK); Host: Theo Heller, MD; Bethesda, MD
January 25-26, 2011
2. University of Wisconsin; Madison, WI; October 12, 2010; Host: Michael Lucey, MD
3. Virginia Commonwealth University, Richmond, VA; March 24-25, 2012
4. University of Massachusetts, Worcester, MA; February 3, 2014; Host: Gyongyi Szabo, MD

MENTORING

Mentor: Hepatology fellowship, Rush University, Chicago. **Jonathon Gochu, MD**; 1995-1996
Mentor: Hepatology fellowship, Rush University, Chicago. **Diana Rowell, MD**; 1996-97
Mentor: GIDH Research Grant. Sri Komanduri (Principal Investigator). 2003-2005. Currently Assistant Professor at Northwestern University Medical School.
Faculty Advisor: Ram Subramanian, MD, 2005-06; currently at Emory University
Mentor: Transplant Hepatology fellowship, University of Chicago: **Rohit Satoskar, MD** 2006-07; currently Assistant Professor of Medicine, Georgetown University
Faculty Advisor: Suki Subramanian, MD, 2006-2010. Now at Columbia University, NY
Faculty Advisor: Joel Pekow, MD, 2007-2010. Now University of Chicago)

Mentor: Transplant Hepatology fellowship, University of Chicago: **Poonam Mishra, MD**
2007-08; currently at FDA in Rockville, MD

Mentor: Transplant Hepatology fellowship, University of Chicago; **Andrew Aronsohn, MD**,
2009-2010; currently Assistant Professor at the University of Chicago

Mentor: Transplant Hepatology fellowship, University of Chicago; **Arjmand Mufti, MD**, 2012-
2013; currently Assistant Professor at University of Texas Southwestern Medical School

Mentor: Transplant Hepatology fellowship; University of Chicago; **Archita Desai, MD**, 2013-
2014. Currently Assistant Professor at University of Arizona

Mentor: Transplant Hepatology fellowship; University of Chicago: **Anour Teriaky, MD**, 2014-
2015. Currently at University of Toronto, Canada

INTERESTS AND HOBBIES

- Oak Park-River Forest Pony Baseball, Board of Directors, 1995-2001
Merritt-Lovett Award recipient as Outstanding Volunteer, 1999
Board Chairman, 1996-1998
- Coached Little League baseball in 1988, 1993, 1994, and 1996.
- Museum of Science & Industry, Medical Advisor 1989-1999
High School Science Fair Judge, 1993-1998
- Competitive running, cycling and swimming.
 - Chicago Triathlon (1989, 1990, 1991, 1992, 2009, 2010),
 - Chicago Marathon (1992, 1993, 2001, 2002, 2015, 2016),
 - Boston Marathon (1994, 2003);
 - Subaru Muskoka Canada Half Ironman Triathlon 70.3 (2010, 2012, 2015)

BIBLIOGRAPHY

PUBLICATIONS- PEER REVIEWED

1. **Jensen, DM**, McFarlane, IG, Portmann, BS, Eddleston, ALWF, and Williams, R: Detection of antibodies directed against a liver-specific membrane lipoprotein in patients with acute and chronic active hepatitis. *N Engl J Med* 299:1-7, 1978.
2. **Jensen, DM**, McFarlane, IG, Nicholson, A, Eddleston, ALWF, and Williams, R: The development of a radioimmunoassay for the detection of antibodies directed against a liver-specific membrane lipoprotein (LSP). *J Clin Lab Immunol* 1:31-35, 1978.
3. Payne, JA, **Jensen, DM**, Codini, RG, Mushawar, IK, and Peterson, D: Acute hepatitis B: a further serologic characterization. *J Clin Gastroenterol* 4:149-156, 1982.
4. Meliconi, R, Perparas, A, **Jensen, DM**, Alberti, A, McFarlane, I, Eddleston, ALWF, and Williams, R: Anti-LSP antibodies in acute liver disease. *Gut* 23:603-607, 1982.
5. Plotzker, R., **Jensen, D**, and Payne, J: Amanita virosa acute hepatic necrosis: treatment with thiocetic acid. *Am J Med Sci* 283:79-82, 1982.
6. **Jensen, DM**, Papadakis, M, and Payne, J: Chronic liver disease manifesting as Waldenstrom's macroglobulinemia. *Arch Int Med* 142:2318-2319, 1982.
7. **Jensen, DM**, Hall, C, and Majewski, T: The plasma membrane origin of liver-specific protein (LSP). *Liver* 3:213-219, 1983.
8. **Jensen, DM**, Peterson, D, Wolfe, L, Hurley, T, Payne, J, and Ogden, J: Antibodies directed against human liver-specific membrane lipoprotein (LSP) in marmosets experimentally infected with the hepatitis A virus. *Clin Exp Immunol* 55:535-540, 1984.
9. Royse, VL, and **Jensen, DM**: The development of an agarose gel electrophoresis technique for the determination of alpha-amylase isoenzymes. *Clin Chem* 30:387-390, 1984.
10. Kessler, H, Chase, R, Harris, A, **Jensen, DM**, and Levin, S: HTLV-III antibodies after hepatitis B vaccination. *Lancet* 1:1506-1507, 1985.
11. Royse, VL, Greenhill, E, Morley, CGD, and **Jensen, DM**: Microheterogeneity of human transferrin by agarose gel electrophoresis with an iron specific stain. *Clin Chem* 32:1983, 1986.
12. **Jensen, DM**, Royse, VL, Newell, J, and Schaffner, J: Use of amylase isoenzymes in laboratory evaluation of hyperamylasemia. *Diag Dis and Sci* 32:561-568, 1987.
13. **Jensen, DM**, Dickerson, D, Linderman, M, Maley, M, and Kessler, H: The relationship between alanine aminotransferase levels and prevalence of serologic markers of hepatitis A, B, and delta in an outpatient population. *Arch of Int Med* 147:1734-1737, 1987.
14. Royse, VL, **Jensen, DM**, Corwin HL: Pancreatic enzymes in chronic renal failure. *Arch Int Med* 147:537-539, 1987.
15. Chase, RA, Pottage, JC, Haber, MH, Kistler, G, **Jensen, D**: Herpes simplex viral hepatitis in adults – two cases and a review of the literature. *Rev Inf Dis* 9:329-333, 1987.
16. Sankary H, Bone R and **Jensen D**: Role of Kupffer cells in modulating cold ischemic preservation injury. *Surgical Forum* 40:352-353, 1989.
17. Mintz, AD, Matalon, TAS, and **Jensen, DM**: Iatrogenic biliovenous fistula. *J Interven Rad* 1:25-27, 1990.
18. McSherry CK and the EDAP Investigators Group: The results of the EDAP multicenter trial of biliary lithotripsy in the United States. *Surgery* 173:461-464, 1991
19. Burck R, Sheldon M, Williams J, Foster P, Bone R, **Jensen D**, Rosenblate H, Sankary H: Limiting access and patient selection in liver transplantation. *NEJM* 326:413, 1992.
20. Deziel DJ, **Jensen DM**, Fabisoff JH, Silver A, Silver B, and Sabesin S: Clinical results of piezoelectric lithotripsy. *The Amer Surgeon* 58:243-249, 1992.
21. Treadwell TL, Keefe EB, Lake J, Read A, Friedman LS, Goldman IS, Howell CD, deMedina M, Schiff ER, **Jensen DM**, and Koff RS: Immunogenicity of two recombinant hepatitis B vaccines in older individuals. *Am J Med* 95:584-588, 1993.

22. Speiss SE, Matalon TA, **Jensen DM**, Rosenblate HJ, Brunner MC, Ganger DR: Transjugular intrahepatic portosystemic shunt in non liver transplant candidates: is it indicated? *Am J Gastroenterology* 1995; 90:1238-1243.
23. McChesney L, **Jensen DM**, Matalon T, Ganger D, Sankary H, Foster P, Williams J: Duodenal varices: A case report and review of the literature. *HPB Surgery* 1995; 9:31-35.
24. Tong MJ, Reddy R, Lee WM, Pockros PJ, Hoefs JC, Keeffe E, Hollinger FB, Heathcote JL, White H, Foust RT, **Jensen DM**, Krawitt EL, Fromm H, Black M, Klein M, Lubina J, Manyak C, Blatt LM and the Consensus Interferon Study Group: Efficacy and safety of consensus interferon (CIFN) in the treatment of chronic hepatitis C: Results of a multicenter phase 3 study. *Hepatology* 1997; 26:747-754.
25. Heathcote EJ, Keeffe E, Lee S, Feinman S, Tong M, Reddy K, Albert D, Witt K, Blatt L and the Consensus Interferon Study Group: Re-treatment of chronic hepatitis C with consensus interferon. *Hepatology* 1998; 27:1136-1143.
26. Ganger DR, Klapman JB, McDonald V, Matalon TA, Kaur S, Rosenblate H, Kane R, Saker M and **Jensen DM**: Transjugular intrahepatic portosystemic shunt (TIPS) for Budd-Chiari or portal vein thrombosis: Review of indications and problems. *Am J Gastroenterology*, 1999; 94:603-608.
27. Cotler SJ, **Jensen DM**, Kesten S: Hepatitis C infection and lung transplantation: A survey of practices. *J Heart Lung Transplant* 1999; 18:456-459.
28. Everson G, **Jensen DM**, Craig JR, van Leeuwen D, Bain V, Ehrinpreis M, Albert D, Joh T, Witt K and the Consensus Interferon Study Group: Efficacy of Consensus interferon in the treatment of patients with chronic hepatitis C and cirrhosis. *Hepatology* 1999; 30:271-276.
29. **Jensen DM**, Krawitt EL, Keeffe EB, Hollinger FB, et al: Biochemical and viral response to consensus interferon (CIFN) therapy in chronic hepatitis C patients: Effect of baseline viral concentration. *Am J Gastroenterol* 1999; 94:3583-3588.
30. Cotler SJ, Wartelle CF, Larson AM, Gretch DR, **Jensen DM**, Carithers RL: Pretreatment symptoms and dosing regimen predict side-effects of interferon therapy for hepatitis C. *J Viral Hepat* 2000;7:211-217.
31. Cotler SJ, Ganger DR, Kaur S, Rosenblate H, Jakate S, Sullivan DG, Ng KW, Gretch DR, and **Jensen DM**: Daily interferon therapy for hepatitis C virus infection in liver transplant recipients. *Transplantation* 2001;71:261-266.
32. Reddy KR, Wright TL, Pockros PJ, Shiffman M, Everson G, Reindollar R, Fried MW, Purdum PP, **Jensen D**, Smith C, Lee WM, Boyer TD, Lin A, Pedder S, Depamphilis J: Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. *Hepatology* 2001; 33:433-438.
33. Teo EK, Terrault N, Luketic V, **Jensen DM**, Keeffe E, Lok ASF, and the HBV-OLT Study Group: Liver transplantation for hepatitis B patients: Do Asians fare worse than whites? *Hepatology* 2001;34:121-125.
34. Cotler SJ, Patil R, McNutt RA, Speroff T, Banaad-Omiotek G, Ganger DR, Rosenblate H, Kaur S, Cotler S, **Jensen DM**. Patients' values for health states associated with hepatitis C and physicians' estimates of those values. *Am J Gastroenterol* 2001;96:2730-6.
35. Patil R, Cotler SJ, Banaad-Omiotek G, McNutt RA, Brown MD, Cotler S, and **Jensen DM**: Physicians' preference values for hepatitis C health states and antiviral therapy: a survey. *BMC Gastroenterol* 2001;1:6.
36. Koukoulis GK, Shen J, Karademir S, **Jensen D** and Williams J: Cholangiocytic apoptosis in chronic ductopenic rejection. *Hum Pathol* 2001;32:823-7.
37. Cotler SJ, Jakate S and **Jensen DM**: Resolution of cirrhosis in autoimmune hepatitis with corticosteroid therapy. *J Clin Gastroenterol* 2001;32:428-30.
38. Cotler SJ, McNutt T, Patil R, Banaad-Omiotek G, Morrissey M, Abrams R, Cotler S, **Jensen DM**, Adult living donor liver transplantation: preferences about donation outside of the medical community. *Liver Transpl* 2001;7:355-340.
39. Cotler SJ, Reddy KR, McCone J, Wolfe DL, Liu A, Craft TR, Ferris MW, Conrad AJ, Albrecht J, Morrissey M, Ganger DR, Rosenblate H, Blatt LM, **Jensen DM**, Taylor MW: An analysis of

- acute changes in interleukin-6 levels after treatment of hepatitis C with consensus interferon. *Journal of Interferon & Cytokine Research* 21(12): 1011-9. (2001)
40. Cotler SJ, Craft T, Ferris M, Morrisey M, McCone J, Reddy KR, Conrad A, **Jensen DM**, Albrecht J, Taylor MW: Induction of IL-1Ra in resistant and responsive hepatitis C patients following treatment with IFN-con1. *J Interferon & Cytokine Research* 2002;22:549-554.
 41. Cotler SJ, Diaz G, Gundlapalli S, Jakate S, Chawla A, Mittal D, Jensik S, **Jensen DM**: Characteristics of hepatitis C in renal transplant recipients. *J Clin Gastroenterol* 2002;35(2):191-195.
 42. Zeuzem, S; Heathcote, E; Shiffman, M; Wright, T; Bain, V; Sherman, M; Feinman, S; Fried M; Rasenack, J; Sarrazin, C; **Jensen, DM**; Lin A; Hoffman, J, Sedarati, F: Determination of sustained virologic response inpatients with interferon alfa for chronic hepatitis C *J Hepatology* 2003;39:106-111
 43. Cotler SJ, Morrissey MJ, Wiley TE, Layden TJ and **Jensen DM**: A pilot study of the combination of cyclosporine A and interferon alfacon-1 for the treatment of hepatitis C in previous nonresponder patients. *J Clin Gastroenterol* 2003;36:352-5.
 44. Zeuzem S, Heathcote EJ, Shiffman ML, Wright TL, Bain V, Sherman M, Feinman SV, Fried M, Rasenack J, Sarrazin C, **Jensen DM**, Lin A, Hoffman JH, Sedarti F: Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis C. *J Hepatol.* 2003 Jul;39(1):106-11.
 45. Cotler SJ, Layden JE, Neumann AU and **Jensen DM**: First phase hepatitis C viral kinetics in previous nonresponder patients. *J Viral Hepatitis* 2003;10:43-9.
 46. Cotler SJ, Cotler S, Gambera M, Benedetti E, **Jensen DM**, Testa G: Adult living donor liver transplantation: perspectives from 100 liver transplant surgeons. *Liver Transpl.* 2003 Jun;9(6):637-44
 47. Sullivan SD, **Jensen DM**, Bernstein DE, Hassanein TI, Foster GR, Lee SS, Cheinquer H, Craxi A, Cooksley G, Klaskala W, Pettit K, Patel KK, Green J. Cost-Effectiveness of Combination Peginterferon alfa-2a and Ribavirin Compared With Interferon alfa-2b and Ribavirin in patients with chronic hepatitis C. *Am J Gastroenterol.* 2004;99(8):1490-6.
 48. **Jensen DM**, Cotler SJ, Lam H, Harb G, Shillington A: A comparison of hepatitis C treatment and outcomes at academic, private and Veterans' Affairs treatment centres. *Aliment Pharmacol Ther.* 2004 Jan;19(1):69-77.
 49. Cotler SJ, Kanji K, Keshavarzian A, **Jensen DM**, Jakate S: Prevalence and significance of autoantibodies in patients with non-alcoholic steatohepatitis. *J Clin Gastroenterol* 2004;38:801-804
 50. Adeyemi OM, **Jensen D**, Attar B, Ghaoui R, Gallagher M, Wolen D, Cotler SJ: Hepatitis C treatment eligibility in an urban population with and without HIV coinfection. *AIDS Patient Care STDS.* 2004 Apr;18(4):239-45.
 51. Cohen SM, Gundlapalli S, Shah A, Rechner J, and **Jensen DM**: The downstream financial effect of hepatology patients in an academic medical center. *Hepatology* 2005;41:968-975.
 52. Adeyemi OM, Attar B, **Jensen DM**, Ghaoui R, Cotler S: Serological markers of autoimmunity in patients infected with hepatitis C virus: impact of HIV co-infection. *HIV Medicine* 2005;6:371-374.
 53. **Jensen DM** and Marcellin P: Rationale and design of the REPEAT study: a phase III, randomized, clinical trial of peginterferon alfa-2a (40 kDa) plus ribavirin in non-responders to peginterferon alfa-2b (12 kDa) plus ribavirin. *Eur J Gastroenterol Hepatol.* 2005;17(9):899-904.
 54. Berg C, Goncales FL Jr, Bernstein DE, Sette H Jr, Rasenack J, Diago M, **Jensen DM**, Graham P, Cooksley G: Re-treatment of Chronic Hepatitis C patients After Relapse: Efficacy of Peginterferon alfa-2a (40KD) and Ribavirin. *J Viral Hepatitis* 2006; 13:435-440
 55. Dickson RC, Terrault NA, Ishitani M, Reddy R, Sheiner P, Luketic V, Soldevila-Pico C, Fried M, **Jensen DM**, Brown R, Horwith G, Brundage R, Lok A: Protective antibody levels and dose requirements for IV 5% NABI Hepatitis B Immune Globulin combined with lamivudine in liver

- transplantation for hepatitis B induced end stage liver disease. *Liver Transplantation* 2006;12:124-133.
56. **Jensen DM**, Morgan TR, Marcellin P, Pockros PJ, Reddy KR, Hadziyannis SJ, Ferenci P, Ackrill AM, Willems B: Early identification of HCV Genotype 1 patients responding to 24 weeks of treatment With Peginterferon Alfa-2a (40KD) plus ribavirin: The 'Super-responders'. *Hepatology* 2006;43:954-960
 57. Sauk J, **Jensen DM**, Mohanty SR, Reau N, Reddy KG, Te HS. Lack of efficacy of pegylated interferon monotherapy for hepatitis C in patients with end-stage renal disease on dialysis. *Gastroenterol Hepatol*. 2006;2(7):504-508
 58. Khiani V, Kelly T, Shibli A, **Jensen DM**, Mohanty S: Acute inflammatory demyelinating polyneuropathy associated with pegylated interferon α 2a therapy for chronic hepatitis C virus infection. *World J Gastroenterol* 2008;14:318-321.
 59. Reau N, Hadziyannis S, Messinger D, Fried M, **Jensen DM** : Early Predictors of anemia with hepatitis C genotype 1 treated with peginterferon alfa 2a and ribavirin. *Amer J Gastro* 2008;103:1981-1988
 60. Kavitt R, Yang V and **Jensen DM**: Cerebral edema and hyperammonemia after transjugular intrahepatic portosystemic shunt placement in a cirrhotic patient. *Clin Gastroenterol and Hepatol* 2008 (9):1054-1056.
 61. Te HS, Anderson AS, Millis JM, Jeevanandam V, **Jensen DM**: Current state of combined heart-liver transplantation in the United States. *J Heart Lung Transplant*. 2008 Jul;27(7):753-9
 62. Mishra P, DeVoss A, Pai R, Hart J, **Jensen D**: Marked flare in hepatic aminotransferases during treatment with pegylated interferon for chronic hepatitis C, genotype 2. A case report. *Dig Dis & Sci* . 2008; Sep 4.
 63. Fried M, **Jensen DM**, Rodriguez-Torres M, Nyburg L, DiBisceglie A, Morgan T, Pockros P, Lin A, Cupelli L, Duff F, Wang K, Nelson D: Randomized, multicenter trial of intensified regimens of peginterferon alfa-2a and ribavirin in HCV patients with poor prognostic factors. *Hepatology* 2008;48:1033-1043.
 64. Mohanty SR, Troy TN, Huo D, O'Brien BL, **Jensen DM**, Hart J.: Influence of ethnicity on histological differences in non-alcoholic fatty liver disease. *J Hepatol*. 2009;50(4):797-804.
 65. Reau N, Hadziyannis SJ, Messinger D, Fried MW, **Jensen DM**.:Early predictors of anemia in patients with hepatitis C genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirin. *Am J Gastroenterol*. 2008;103(8):1981-8
 66. Nelson DR, Davis GL, Jacobson I, Everson GT, Fried MW, Harrison SA, Hassanein T, **Jensen DM**, Lindsay KL, Terrault N, Zein N.: Hepatitis C virus: a critical appraisal of approaches to therapy. *Clin Gastroenterol & Hepatol*. 2009;7(4):397-414.
 67. **Jensen DM**; Marcellin P, Freilich B, Andreone P, Di Bisceglie A, Brandaño-Mello CE, Reddy KR, Craxi A, Oliveira Martin A, Teuber G, Messinger D, Thommes JA, Tietz A: Re-treatment of Patients With Chronic Hepatitis C Who Do Not Respond to Peginterferon-a2b: A Randomized Trial. *Ann Int Med*. 2009;150(8):528-540
 68. Singal AG, Volk ML, **Jensen DM**, DiBisceglie A, Schoenfeld PS: A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with chronic hepatitis C. *Clin Gastroenterol Hepatol*. 2010;8:280-288.
 69. Rodriguez-Torres M, Sulkowski MS, Chung RT, Hamzeh FM and **Jensen DM**: Factors associated with rapid and early virologic response to peginterferon alfa-2a/ribavirin treatment in HCV genotype 1 patients representative of the general chronic hepatitis C population. *J Viral Hepatitis*, 2010; 17:139-147.
 70. Kayhan A, Ilkchoui Y, Venu N, **Jensen DM**, Oto A: Multiple Abdominal Vascular Anomalies in a Patient with Alagille Syndrome. *J Vasc Interv Radiol*. 2010;21:937-40
 71. Aronsohn A and Jensen, D "HCV Eradication: Implications for Disease Resolution" *Current Hepatitis Rep*, 2011, 10:27-32

72. Reau N, Satoskar R, Te H, DeVoss A, Elsen C, Reddy G, Mohanty S, **Jensen DM**: Evaluation of early null response to pegylated interferon and ribavirin as a predictor of therapeutic nonresponse in patients undergoing treatment for chronic hepatitis C. *Amer J Gastroenterol*, 2011; 106:452-458.
73. Kayhan A, Venu N, Lakadamyali H, **Jensen D**, Oto A. Multiple progressive focal nodular hyperplasia lesions of liver in a patient with hemosiderosis. *World J Radiol*. 2010 Oct 28;2(10):405-9.
74. Aronsohn A and **Jensen DM**: Distributive justice and the arrival of new antiviral agents: Who should be first in line? *Hepatology* 2011 Jun;53(6):1789-91.
75. DiMartino V, Richou C, Cervoni J-P, Sanchez-Tapias J, **Jensen DM**, Mangia A, Buti M, Sheppard F, Ferenci P, Thevenot T: Reposne-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: meta-analyses of randomized controlled trials and implications for the future. *Hepatology* 2011 Sep 2;54(3):789-800
76. Nelson D, Zeuzem S, Andreone P, Ferenci P, Herring R, **Jensen DM**, Marcellin P, Pockros P, Rodriguez-Torres M, Rossaro L, Rustgi V, Sepe T, Sulkowski M, Thomason I, Yoshida E, Chan A, Hill G: Balapiravir plus Peginterferon Alfa-2a (40KD)/Ribavirin in a randomized trial of hepatitis C genotype 1 patients. *Ann Hepatol*. 2012 Jan;11(1):15-31
77. Reau N, Hamzeh FM, Lentz E, Zhou X, **Jensen DM**.: Characterization of nonrapid virologic response patients infected with HCV genotype 1 who may relapse after standard therapy with peginterferon plus ribavirin. *J Viral Hepat*. 2012 Feb;19(2):94-102. doi: 10.1111/j.1365-2893.2010.01422.x. Epub 2011 Jan 12
78. Marcellin P, Reau N, Ferenci P, Hadziyannis S, Messinger D, Tatsch F, **Jensen DM**. Refined prediction of week 12 response and SVR based on week 4 response in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) and ribavirin. *J Hepatol*. 2012 Jun;56(6):1276-82
79. Marcellin P, Roberts SK, Reddy KR, Harrison SA, **Jensen DM**, Hadziyannis S, Diago M, Weltman M, Messinger D, Tatsch F, Rizzetto M.: Safety profile of standard- versus high-dose peginterferon alfa-2a plus standard dose ribavirin in patients infected with HCV genotype 1 or 4: pooled analysis from five randomised studies *Expert Opin Drug Saf*. 2012 Nov;11(6):901-9.
80. Nelson DR, **Jensen DM**, Sulkowski MS, Everson G, Fried MW, Gordon SC, Jacobson I, Reau NS, Sherman K, Terrault N, Thomas D. Hepatitis C virus: A critical appraisal of newer approaches to therapy. *Hepat Res Treat*. 2012;2012:138302.
81. Yang L, Aronsohn A, Hart J, **Jensen D**: Herbal hepatotoxicity from Chinese skullcap: A case report. *World J Hepatol*. 2012 Jul 27;4(7):231-3.
82. Desai AP, Reau N, Reddy KG, Te HS, Mohanty S, Satoskar R, Devoss A, **Jensen D**: Persistent spontaneous bacterial peritonitis: a common complication in patients with spontaneous bacterial peritonitis and a high score in the model for end-stage liver disease. *Therap Adv Gastroenterol*. 2012 Sep;5(5):275-83.
83. Te HS, Dasgupta KA, Cao D, Satoskar R, Mohanty SR, Reau N, Millis JM, **Jensen DM**. Use of immune function test in monitoring immunosuppression in liver transplant recipients. *Clin Transplant*. 2012 Nov;26(6):826-32.
84. Aronsohn A and **Jensen DM**: Informed deferral: A moral requirement for entry into the hepatitis C virus treatment warehouse. *Hepatology*. 2012 Nov;56(5):1591-2. doi: 10.1002/hep.25957
85. Marcellin P, Cheinquer H, Curescu M, Dusheiko GM, Ferenci P, Horban A, **Jensen D**, Lengyel G, Mangia A, Ouzan D, Puoti M, Rodriguez-Torres M, Shiffman ML, Schmitz M, Tatsch F, Rizzetto M: High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHECY cohort confirm results from randomized clinical trials. *Hepatology*. 2012 Dec;56(6):2039-50.
86. Wedemeyer H, **Jensen DM**, Godofsky E, Mani N, Pawlotsky JM, Miller V; on behalf of the Definitions/Nomenclature Working Group* of the HCV DrAG (HCV Drug Development Advisory Group), under the auspices of the Forum for Collaborative HIV Research: Recommendations for standardized nomenclature and definitions of viral response in trials of HCV investigational agents. *Hepatology*. 2012 Dec;56(6):2398-403.

87. Marcellin P, Craxi A, Brando-Mello CE, Di Bisceglie A, Andreone P, Freilich B, Reddy KR, Martin AO, Teuber G, Messinger D, Hooper G, Wat C, Tatsch F, and **Jensen DM**: Predicting early and sustained virological responses in prior non-responders to pegylated interferon alfa-2b plus ribavirin re-treated with peginterferon alfa-2a plus ribavirin and the benefit-risk ratio of retreatment. *J Clin Gastro* 2013 Feb 24. PMID: 23442834 [Epub ahead of print]
88. Pockros PJ, **Jensen D**, Tsai N, Taylor R, Ramji A, Cooper C, Dickson R, Tice A, Kulkarni R, Vierling JM, Lou Munson M, Chen YC, Najera I, Thommes J; JUMP-C Investigators. JUMP-C: a randomized trial of mericitabine plus pegylated interferon alpha-2a/ribavirin for 24 weeks in treatment-naïve HCV genotype 1/4 patients. *Hepatology* 2013;58:514-523
89. Wedemeyer H, Jensen D, Herring R Jr, Ferenci P, Ma MM, Zeuzem S, Rodriguez-Torres M, Bzowej N, Pockros P, Vierling J, Ipe D, Munson ML, Chen YC, Najera I, Thommes J; PROPEL Investigators. PROPEL: a randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-naïve HCV genotype 1/4 patients. *Hepatology* 2013;58:524-537
90. Lawitz E, Laezari JP, Hassanein T, Kowdley KV, Poordad FF, Sheikh AM, Afdhal NH, Bernstein DE, Dejesus E, Freilich B, Nelson DR, Dieterich DT, Jacobson IM, **Jensen D**, Abrams GA, Darling JM, Rodriguez-Torres M, Reddy KR, Sulkowski MS, Bzowej NH, Hyalnd RH, Mo H, Lin M, Mader M, Hindes R, Albanis E, Symonds WT, Berrey MM, Muir A: Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naïve patients with genotypes 1, 2, and 3 hepatitis C infection: a randomized, double-blind, phase 2 trail. *Lancet Infect Dis*. 2013 Mar 14. [Epub ahead of print]
91. Fried MW, **Jensen DM**.: The FDA, bridging data, and hepatitis C. *Hepatology*. 2013 Mar;57(3):875-7. doi: 10.1002/hep.26177.
92. Aronsohn A, Muir AJ, Swan T, **Jensen DM**.: Is the HCV pipeline heading in the right direction? *Gastroenterology*. 2013 Mar;144(3):482-5. doi: 10.1053/j.gastro.2013.01.018. Epub 2013 Jan 23.
93. Aronsohn A, **Jensen DM**.: Expanding access to HCV care: A call to deconstruct individualized therapy. *Hepatology*. 2013 Jun 20. doi: 10.1002/hep.26590. [Epub ahead of print]
94. Verma S, Jensen D, Hart J and Mohanty SR: Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD). *Liver Int* 2013;33:1398-1405
95. **Jensen DM** and Nathanson M: Faster than a speeding bullet. *Hepatology*. Article first published online: 4 FEB 2014 | DOI: 10.1002/hep.27007
96. Aronsohn A, Reau N and **Jensen DM**: Preparing for the uncertain yet inevitable off-label combinations of antiviral agents in hepatitis C virus. *Hepatology* 2014;59:1688-1691
97. **Jensen DM**: Advances in combination regimens in the management of HCV infection. *Gastroenterol Hepatol (NY)* 2014;10:134-136
98. Zeuzem S, Jacobson I, Baykal T, Marinho R, Poordad F, Bouliere M, Sulkowski M, Wedemeyer H, Tam E, Desmond P, **Jensen D**, DiBisceglie A, Varunok P, Hassanein T, Xiong J, Pilot-Matais T, DaSilva-Tillmann B, Larsen L, Podsadecki T and Bernstein B: Retreatment of HCV with ABT450/r-ombitasvir and dasabuvir with ribavirin. *N Engl J Med* 2014;370:1604-1614.
99. Desai A, Satoskar R, Appannagari A, Reddy KG, Te HS, Reau NS, Meltzer DO and **Jensen DM**: Co-management between hospitalist and hepatologist improves the quality of care of inpatients with chronic liver disease. *J Clin Gastroenterol* 2014;48:30-36
100. Mikolajczyk AE, Aronsohn AA, McConville JF, **Jensen DM**, Farnan JM. A call to action: The need for hepatology-focused educational interventions in Internal Medicine Residency training. *Hepatology*. 2015 Aug;62(2):655-6.
101. Welch NM, **Jensen DM**: Pegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis C. *Liver Int*. 2015 Jan;35 Suppl 1:11-7. doi: 10.1111/liv.12715. Review.
102. Feld J, Jacobson I, **Jensen DM**, Foster G, Pol s, Tam E, Jablkowski M, Berak H, Vierling J, Yoshida E, Perez-Gomez H, Le Pogam S, Najera I, Eng S, Yin Lim C, Shulman N and Yetzer E: Randomised study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin. *J Hepatol* 2014; Sep 16. pii: S0168-8278(14)00667-9. doi: 10.1016/j.jhep.2014.09.013. [Epub ahead of print]

103. Pho MT, **Jensen DM**, Meltzer DO, Kim AY, Linas BP.: Clinical impact of treatment timing for chronic hepatitis C infection: a decision model. *J Viral Hepat.* 2015 Aug;22(8):630-8.
104. **Jensen DM**, et al: Daclatasvir and Asunaprevir Plus Peginterferon Alfa and Ribavirin in HCV Genotype 1 or 4 Non-responders. *J Hepatol.* 2015 Jul;63(1):30-7.
105. Sengupta S, Wroblewski K, Aronsohn A, Reau N, Reddy KG, **Jensen D**, Te H: Screening for Zinc Deficiency in Patients with Cirrhosis: When Should We Start? *Dig Dis Sci.* 2015 Oct;60(10):3130-5.
106. Fritz CD, Adebajo C, Aronsohn A, **Jensen DM**: A New-Onset Rash in the Setting of Rifaximin Treatment for Hepatic Encephalopathy. *ACG Case Rep J.* 2014 Oct 10;2(1):42-4.
107. **Jensen DM**, Brunda M, Elston R, Gane EJ, George J, Glavini K, Hammond JM, Le Pogam S, Nájera I, Passe S, Piekarska A, Rodriguez I, Zeuzem S, Chu T; ANNAPURNA study investigators. *Liver Int.* 2015 Oct 31. doi: 10.1111/liv.12997
108. AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. *Hepatology.* 2015 Sep;62(3):932-54.
109. Chiu C, Berg M, Lee D, Aronsohn A, Cheng K, Collier K, Forberg K, Frankel M, Marcinkus M, Naccache S, Dawson G, Brennan C, Hackett J, **Jensen DM**: Discovery of a Novel Human Pegivirus in Blood Associated with Hepatitis C Virus Co-Infection. *PLOS Pathogens* 2015 (in press)
110. **Jensen DM**, Brunda M, Elston R, et al: Interferon-free regimens containing sofosbuvir for patients with genotype 1 chronic hepatitis C: a randomized, multicenter study. *Liver Int* 2015 (in press) DOI: 10.1111/liv.12997
111. Mikolajczyk AE, Farnan JM, McConville JF, **Jensen DM**, Reddy KG, Te HS, Reau N, Aronsohn AI: Novel Educational Interventions in Residency Increase Knowledge of Chronic Liver Disease and Career Interest in Hepatology. *Hepatology.* 2016 Aug 10. doi: 10.1002/hep.28741
112. Kataria Y, Deaton RJ, Enk E, Jin M, Petrauskaite M, Dong L, Goldenberg JR, Cotler SJ, **Jensen DM**, van Breemen RB, Gann PH.: Retinoid and carotenoid status in serum and liver among patients at high-risk for liver cancer. *BMC Gastroenterol.* 2016 Feb 29;16:30. doi: 10.1186/s12876-016-0432-5.
113. **Jensen DM**, Asselah T, Dieterich D, Foster GR, Sulkowski MS, Zeuzem S, Mantry P, Yoshida EM, Moreno C, Ouzan D, Wright M, Morano LE, Buynak R, Bourlière M, Hassanein T, Nishiguchi S, Kao JH, Omata M, Paik SW, Wong DK, Tam E, Kaita K, Feinman SV, Stern JO, Scherer J, Quinson AM, Voss F, Gallivan JP, Böcher WO, Ferenci P.: Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials. *Ann Hepatol.* 2016 May-Jun;15(3):333-49.
114. Kao JH, **Jensen DM**, Manns MP, Jacobson I, Kumada H, Toyota J, Heo J, Yoffe B, Sievert W, Bessone F, Peng CY, Roberts SK, Lee YJ, Bhore R, Mendez P, Hughes E, Noviello S.: Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysis. *Liver Int.* 2016 Jul;36(7):954-62.

INVITED REVIEWS and NON PEER-REVIEWED

1. Ebie, N, **Jensen, DM**, et al: Primary hepatocellular carcinoma [REVIEW]. *Medical and Pediatric Oncology* 14:281-287, 1986.
2. **Jensen DM** and Koff R: Abnormal liver tests – what next? *Patient Care* 26:143-170, 1992.
3. **Jensen DM**: Liver Transplantation for Hepatocellular Carcinoma. *Clinical Advances in Gastroenterology*, October, 1993.
4. Fregia A and **Jensen DM**: Evaluation of abnormal liver tests [REVIEW]. *Comprehensive Therapy* 20:50-54, 1994.
5. Bhuvu M, Ganger D, **Jensen DM**: Spontaneous bacterial peritonitis: an update on evaluation, management and prevention [REVIEW]. *Am J Med.* 97:169-175, 1994.
6. **Jensen DM**: Hepatitis C [REVIEW] *J Insurance Med* 1996; 27:116-123.

7. Rowell D and **Jensen DM**: The significance of normal ALT levels in patients with viral hepatitis. (REVIEW) *Viral Hepatitis Reviews* 1997; 3:189-199.
8. Kaplan M, Gawrieh S, Cotler SJ, **Jensen DM**: Neutralizing antibodies in hepatitis C virus infection: a review of immunological and clinical characteristics. *Gastroenterology*. 2003 Aug;125(2):597-604. Review
9. Te H, Randall G and **Jensen D**: Ribavirin: Mechanism of Action (Review). *Gastroenterology and Hepatology*, 2007
10. Satoskar R and **Jensen DM**: Retreatment of chronic hepatitis C in previous non-responders and relapsers. *Expert Opin Pharmacother*. 2007 Oct;8(15):2491-503. Review.
11. Reau NS, **Jensen DM**. Current Developments in the Treatment of Hepatitis B and C (Review) *US Infectious Diseases*. 2007;1:29-30
12. Martin P and **Jensen DM**: Ribavirin in the Treatment of Chronic Hepatitis C: A Review, *J Gastro & Hepatol*. 2008 23: 844–855
13. Reau NS, **Jensen DM**. Vanishing Bile Duct Syndrome and Adult Ductopenia. *Clinics in Liver Disease*. 2008;12:203-217.
14. Mishra P and **Jensen DM**: Hepatitis C: Current and Future Therapies. *Mount Sinai Journal of Medicine* 2008 Aug;75(4):405-14.
15. **Jensen DM** and Ascione A: Future Directions in Therapy for Chronic Hepatitis C. *Antiviral Therapy* 2008;13 Suppl 1:31-36.
16. **Jensen DM**: Individualizing HCV Treatment with Peginterferon and Ribavirin: What needs to be done? (Editorial) *Ther Adv Gastro* 2009;2:5-10.
17. MacGreal N and **Jensen DM**: Editorial: Sustained viral response after interferon-based therapy in chronic hepatitis C: more evidence to support a life-long cure. *Liver Int*. 2009;29(4):481-2
18. **Jensen DM**. Treatment duration for genotypes 2 and 3: still confusing after all these years. *J Clin Gastroenterol*. 2010 Sep;44(8):527-8.
19. **Jensen DM**: A new era of hepatitis C therapy begins.(Requested Editorial) *N Engl J Med* 2011;364:1272-1274
20. Aronsohn A and **Jensen, D** "Hepatobiliary Manifestations of Critically Ill and Postoperative Patients" *Clinics in Liver Disease*, Feb 2011, 15(1):183-97.
21. Aronsohn A and **Jensen D** "The Long-term Horizon Patients Who Will Remain Untreated in the Era of Triple Therapy" *Clinical Liver Disease*, 2012, 1(1):20-23
22. Jacobson IM, Pawlotsky JM, Afdhal NH, Dusheiko GM, Fornis X, **Jensen DM**, Poordad F, Schulz J.: A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C. *J Viral Hepat*. 2012 May;19 Suppl 2:1-26. doi: 10.1111/j.1365-2893.2012.01590.x. Review.
23. **Jensen DM**, Pol S.: IL28B genetic polymorphism testing in the era of direct acting antivirals therapy for chronic hepatitis C: ten years too late? *Liver Int*. 2012 Feb;32 Suppl 1:74-8.
24. Dabbouseh NM, **Jensen DM**.: Future therapies for chronic hepatitis C. *Nat Rev Gastroenterol Hepatol*. 2013 May;10(5):268-76. doi: 10.1038/nrgastro.2013.17. Epub 2013 Feb 19.
25. Petty LA, Steinbeck JL, Pursell K and Jensen DM: Human immunodeficiency virus and coinfection with hepatitis B and C. *Infect Dis Clin North Am* 2014; Sep;28(3):477-99. doi: 10.1016/j.idc.2014.05.005
26. Aronsohn A and **Jensen DM**: Preparing for the uncertain yet inevitable: off-label combinations of antiviral agents in hepatitis C virus. *Hepatology*; 59:1688-91
27. Aronsohn A and **Jensen D**: Interferon-combination strategies for the treatment of chronic hepatitis C. *Semin Liver Dis* 2014;34:30-36
28. **Jensen DM**: Advances in combination regimens in the management of HCV infection. *Gastroenterol Hepatol (N.Y.)*. 2014;10:134-6
29. **Jensen DM** and Nathanson MH: Faster than a speeding bullet. *Hepatology* 2014;59:1246-9
30. Reau NS and **Jensen DM**: Sticker shock and the price of new therapies for hepatitis C: Is it worth it? *Hepatology* 2014;59:1246-9
31. Welch N and **Jensen DM**: Pegylated interferon based therapy with second-wave direct-acting
32. antivirals in genotype 1 chronic hepatitis C. *Liv Int* 2015 (in press)

33. Mikolajczyk AE, Aronsohn AA, McConville JF, **Jensen DM**, Farnan JM: A call to action: The need for hepatology-focused educational interventions in internal medicine residency training. *Hepatology*. 2014 Nov 1. doi: 10.1002/hep.27591
34. **Jensen DM**, Sebhatu P, Reau NS.: Generic medications for hepatitis C. *Liver Int*. 2016 Jul;36(7):925-8. doi: 10.1111/liv.13120.

BOOKS, CHAPTERS EDITED

1. **Jensen, DM**: Comparison of anti-LSP responses in predictable and idiosyncratic drug reactions. In, Immune Reactions in Liver Disease, (eds) ALWF Eddleston, JCP Weber, R. Williams. Turnbridge Wells, England, Pitman Medical Publish Co., Ltd., p. 265, 1979.
2. **Jensen, DM**: Portal-systemic encephalopathy and hepatic coma [REVIEW]. In, Medical Clinics of North America, 70:1081-1092, 1986.
3. Deziel, DJ and **Jensen DM**: Gallstone lithotripsy. In, Problems in General Surgery Vol 7, No 3, (ed) S.G. Economou. J.B. Lippincott Co., Philadelphia, pp390-399, 1989.
4. **Jensen, DM** and Sabesin, SM: Acute pancreatitis. In Current Therapy in Critical Care Medicine, (ed) J. Parillo. B.C. Decker Inc., Philadelphia pp275-278, 1991.
5. **Jensen DM**: The Liver. In, Rush University Review of Surgery, 2nd edition, (eds) S.G. Economou, D. Deziel, T. Witt, S. Bines, T. Saclarides, E. Staren and T. Velasco, W.B. Saunders Co., Philadelphia, pp 294-302, 1993.
6. **Jensen DM**: Chronic Pancreatitis. Chapter 59-B. In, Quick Reference to Internal Medicine: Outline Format, (eds) Bone, RC and Rosen, RL, Igaku-Shoin Ltd. Publishing, New York, pp 809-810, 1994.
7. **Jensen DM**: Viral Hepatitis. Chapter 61-B. In, Quick Reference to Internal Medicine: Outline Format, (eds) Bone, RC and Rosen, RL, Igaku-Shoin Ltd. Publishing, New York, pp 819-820, 1994.
8. **Jensen DM and Sabesin S**: Alcoholic Liver Disease. Chapter 61-C. In, Quick Reference to Internal Medicine: Outline Format, (eds) Bone, RC and Rosen, RL, Igaku-Shoin Ltd. Publishing, New York, pp 821-824, 1994.
9. **Jensen DM**: Liver Biopsy. Chapter 55-E. In, Quick Reference to Internal Medicine: Outline Format, (eds) Bone, RC and Rosen, RL, Igaku-Shoin Ltd. Publishing, New York, pp727-728, 1994.
10. **Jensen DM**: Acute Pancreatitis. Chapter 59-E. In, Quick Reference to Internal Medicine: Outline Format, (eds) Bone, RC and Rosen, RL, Igaku-Shoin Ltd. Publishing, New York, pp 805-808, 1994.
11. **Jensen DM**: Chronic Hepatitis. Chapter 61-D. In, Quick Reference to Internal Medicine: Outline Format, (eds) Bone, RC and Rosen, RL, Igaku-Shoin Ltd. Publishing, New York, pp 825-826, 1994.
12. **Jensen DM**: Primary Sclerosing Cholangitis. Chapter 61-F. In, Quick Reference to Internal Medicine: Outline Format, (eds) Bone, RC and Rosen, RL, Igaku-Shoin Ltd. Publishing, New York, pp 829-830, 1994.
13. **Jensen DM**: Hepatic Encephalopathy. Chapter 61-I. In, Quick Reference to Internal Medicine: Outline Format, (eds) Bone, RC and Rosen, RL, Igaku-Shoin Ltd. Publishing, New York, pp 837-838, 1994.
14. **Jensen DM**: Hepatic Transplantation. Chapter 61-L. In, Quick Reference to Internal Medicine: Outline Format, (eds) Bone, RC and Rosen, RL, Igaku-Shoin Ltd. Publishing, New York, pp 845-846, 1994.
15. **Jensen DM**: Granulomatous Diseases. Chapter 62. In, Quick Reference to Internal Medicine: Outline Format, (eds) Bone, RC and Rosen, RL, Igaku-Shoin Ltd. Publishing, New York, pp 847-849, 1994.
16. **Jensen DM**: Acute Liver Failure. In, Current Therapy in Critical Care Medicine, (ed) Joseph Parillo, Mosby Yearbook Publishers, St Louis, pp346-349, 1997.

17. Cotler S and **Jensen D**: Management of Chronic Hepatitis C. In, Medical Management of Liver Disease (ed) Edward Krawitt, Marcel Dekker, Inc. pp99-114, 1999.
18. Angtuaco T and **Jensen DM**: Hepatitis B and Hepatitis C Coinfection. In, Chronic Viral Hepatitis, (eds) Raymond Koff and George Wu. 2001
19. Cotler SJ and **Jensen DM**: Hepatitis C and HIV coinfection. Clinics in Liver Dis 5:1045-1061; 2001
20. Sotil EU, **Jensen DM**: Serum enzymes tests in the evaluation of cholestasis. Clinics in Liver Disease, 8:41-54, 2004
21. Reau NS, **Jensen DM**: Vanishing Bile Duct Syndrome, Clinics in Liver Dis 2008;12:203-217
22. Mohanty S and **Jensen DM**: Tumor Markers and Molecular Biology. In, HEPATOCELLULAR CARCINOMA: A Practical Approach. (des) Al Knawy B, Reddy R, Bolondi L. Informa Healthcare. Pp62-81; 2009
23. **Jensen DM**. Treatment duration for genotypes 2 and 3: still confusing after all these years. J Clin Gastroenterol. 2010 Sep;44(8):527-8.
24. Controversies in Hepatology: The Experts Analyze Both Sides. (ed) **Jensen DM**; SLACK, Inc. 2011
25. Aronsohn A, **Jensen D**. Hepatobiliary manifestations of critically ill and postoperative patients. Clin Liver Dis. 2011 Feb;15(1):183-97. Review.
26. Te HS and **Jensen DM**: Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis. 2010 Feb;14(1):1-21, vii. Review.
27. Jenkins ET, **Jensen DM**. The importance of rapid viral suppression in the era of directly acting antiviral therapy for hepatitis C virus. Infect Dis Clin North Am. 2012 Dec;26(4):879-91. doi: 10.1016/j.idc.2012.08.007.
28. Hepatitis C. (eds) **Donald M Jensen** and Nancy Reau; Oxford University Press; 2012.
29. Petty LA, Steinbeck JL, Pursel K and **Jensen DM**: Human Immunodeficiency Virus and Coinfection with Hepatitis B and C. Infect Dis Clin N Am 28 (2014) 477–499
30. Newton J, Aronsohn A and **Jensen DM**: Liver dysfunction in critically ill patients.2015

COMPUTER LEARNING:

1. Rowell D and **Jensen DM**: Selection of Patients for Liver Transplantation. UpToDate v5.2, CD-ROM educational software, 1998.
2. Cotler S and **Jensen DM**: Treatment of Acute Rejection in Liver Transplant Recipients. UpToDate v5.2, CD-ROM educational software, 1998.
3. Kaur S and **Jensen DM**: Diagnosis of acute cellular rejection in liver transplant recipients. UpToDate v5.2, CD-ROM educational software, 1998.
4. Cotler S and **Jensen D**: Long-term complications of liver transplantation. UpToDate v5.2, CD-ROM educational software, 1998.
5. Patil R and **Jensen DM**: Infectious complications following liver transplantation. UpToDate, vol 5.3, CD-ROM educational software, 1999.
6. Reau N and **Jensen D**: Ductopenia and Vanishing Bile Duct Syndromes. UpToDate 2007

MEDIA AND LAY PRESS AND VIDEO

1. <https://www.youtube.com/watch?v=fnR7Jvkqsy4>
2. <https://www.youtube.com/watch?v=skwg6Kkr3l0>
3. https://www.youtube.com/watch?v=qfRfOTU1j_o
4. <https://www.youtube.com/watch?v=THCtapEEqwQ>
5. <https://www.youtube.com/watch?v=K8JvIUWAn6M>
6. <https://www.youtube.com/watch?v=pmm0AeO71Eg>
7. <http://wgntv.com/2013/03/07/hepatitis-c-cure/>
8. <https://givetomedicine.uchicago.edu/donor-stories/hepatitis-c-controllable-curable>

9. <http://www.healio.com/hepatology/hepatitis-c/news/online/%7B844ec2ae-be3e-4867-a33d-9a8739e5661a%7D/real-world-advanced-disease-hcv-treatments-highlighted-at-the-liver-meeting-2014>
10. <http://www.medscape.com/viewarticle/843740>
11. <http://www.medpagetoday.com/InfectiousDisease/Hepatitis/47152>
12. <http://www.chicagomag.com/Chicago-Magazine/January-2008/Chicagos-Top-Doctors/Hepatitis-Seer/>
13. <http://www.everydayhealth.com/hs/hepatitis-c-living-well/exercise-benefits/>
14. [http://www.news-medical.net/news/20130729/Hepatitis-C-\(HCV\)-testing-for-baby-boomers-an-interview-with-Dr-Donald-Jensen-Director-Center-for-Liver-Diseases-University-of-Chicago.aspx](http://www.news-medical.net/news/20130729/Hepatitis-C-(HCV)-testing-for-baby-boomers-an-interview-with-Dr-Donald-Jensen-Director-Center-for-Liver-Diseases-University-of-Chicago.aspx)
15. <http://newsatjama.jama.com/2014/08/11/guideline-patients-with-liver-disease-should-be-first-in-line-for-new-hepatitis-c-treatments/>
16. <http://www.medscape.com/viewarticle/826635>
17. <https://www.youtube.com/watch?v=2k-nHS5Xdoc>
18. <http://tv360.mobi/video/late-breaking-session-on-hepatitis-c-virus-the-liver-meeting-2013/37216/>
19. <https://www.youtube.com/watch?v=ODqMolabnEo>
20. https://www.youtube.com/watch?v=_ESYItSAKBE
21. <https://www.youtube.com/watch?v=Kj3GDPEdDks>
22. <https://www.youtube.com/watch?v=6V8tddEzWcQ>
23. <https://www.youtube.com/watch?v=wZuWGfCjHK0>
24. <http://www.healio.com/hepatology/hepatitis-c/news/online/%7B1143eb3d-0568-4b68-a34b-999bffeaa3a3%7D/jensen-discusses-high-svr-rates-in-hallmark-quad-trial>
25. <https://www.youtube.com/watch?v=kfyQVIM4ADs>
26. <http://hepatitis.about.com/od/community/ss/The-High-Price-of-Hepatitis-C-Medications.htm>
27. <http://hepatitis.about.com/od/treatment/fl/What-to-do-if-hepatitis-C-treatment-coverage-is-denied.htm>
28. <http://hepatitis.about.com/od/treatment/fl/New-FDA-Warning-on-Viekira-Pak-and-Technivie.htm>
29. <http://hepatitis.about.com/od/overview/fl/ALT-Why-do-we-measure-it-and-what-does-it-tell-us.htm>
30. <http://hepatitis.about.com/od/treatment/fl/Coffee-consumption-and-Liver-Disease.htm>
31. <http://hepatitis.about.com/od/treatment/fl/Medical-Tourism-Should-you-get-your-hepatitis-C-medicine-from-India.htm>
32. <http://hepatitis.about.com/od/treatment/fl/Is-cure-of-hepatitis-C-with-medications-possible.htm>
33. <http://hepatitis.about.com/od/symptoms/fl/Why-is-cirrhosis-bad-What-is-it-about-cirrhosis-that-can-kill-people.htm>
34. <http://hepatitis.about.com/od/overview/fl/The-Senate-Finance-Committee-Report-on-Gilead-HCV-Drug-Pricing.htm>
35. http://www.pharmacypracticenews.com/ViewArticle.aspx?d=Clinical&d_id=50&i=November+2015&i_id=1242&a_id=34375
36. <http://hepatitis.about.com/bio/Donald-Jensen-MD-145124.htm>
37. <http://www.chicagotribune.com/business/careers/chi-donald-m-jensen-president-american-liver-foundationgreat-lakes-20140624-story.html>
38. http://www.itvisus.com/programs/hbhm/episode_1110_The_Future_of_Hepatitis_C.asp
39. Prevention Magazine on MSNBC <http://www.msnbc.msn.com/id/22575539/> 1-10-08
40. InTimesTV : Update on Liver Disease <http://www.intimetv.com/medical/iim.cfm> 1-5-08
41. <http://www.uchospitals.edu/news/2007/20071217-top-doctors.html>

PUBLISHED ABSTRACTS (incomplete)

1. **Jensen, DM**, McFarlane, IG, Eddleston, ALWF, and Williams, R: Radioimmunoassay for antibodies to human liver-specific membrane lipoprotein (LSP) in chronic active hepatitis and chronic persistent hepatitis. Gut 18:A978, 1977.
2. **Jensen, DM**, Majewski, T, Payne, J, and Peterson, D: Anti-LSP antibodies in acute viral hepatitis A. Gastroenterology 77:A19, 1979.
3. Hanlon, D, **Jensen, DM**, Peterson, D, et al: A solid-phase radioimmunoassay for the detection of IgA antibodies to the hepatitis A virus. Gastroenterology 80:A1335, 1981.
4. **Jensen, DM**, Hall, C, Hess, P, and Payne, J: The plasma membrane origin of liver-specific protein (LSP). Hepatology 1:521, 1981.
5. Payne, JA, **Jensen, DM**, Giacchino, R, Peterson, D, and Mushawar, IR: Serologic studies in resolving acute hepatitis B. Gastroenterology 77:A31, 1979.
6. Meliconi, RM, Alberti, A, **Jensen, D**, McFarlane, I, Eddleston, ALWF, and Williams, R: Anti-LSP antibody in acute viral hepatitis. Gut 19:A994, 1978.
7. **Jensen, DM**, Peterson, D, Wolfe, L, and Payne, J: Anti-LSP autoantibodies in marmosets experimentally infected with the hepatitis A virus (HAV): an animal model for investigation of viral-induced LSP autoantibodies. Hepatology 2:679, 1982.
8. Hanlon, D, **Jensen, D**, Peterson, D, Wolfe, L, and Levin, S: A radioimmunoassay for the detection of hepatitis A virus-specific IgA antibodies: results in experimentally infected marmosets. Hepatology 2:679, 1982.
9. Royse, V, and **Jensen, D**: Serum amylase isoenzymes. I Development and analysis of a new method. Clin Res 288A, 1983.
10. **Jensen, DM**, Royse, VL, Newell, J, Schaffner, J, and Payne, J: Determination of amylase isoenzymes by an improved agarose gel electrophoresis technique: results in 37 consecutive hyperamylasemic patients. Gastroenterology 84:1198, 1983.
11. Rosenbaum, A, Royse, V, **Jensen, D**, and Payne, J: The tissue sources of amylase in the marmoset. Dig Dis and Sci 28:946, 1983.
12. Rosenbaum, A, Royse, V, **Jensen, D**, and Payne, J: The tissue source of amylase in the marmoset. Dig Dis and Sci 28:946, 1983.
13. Royse, VL, and **Jensen, DM**: Laboratory and clinical evaluation of a sensitive radioimmunoassay for lipase (NuClipase, NuClin Diagnostics). Clin Chem 30:1058, 1984.
14. Hakim, A, **Jensen, D**, Bardawil, L, Kessler, Harris, A, and Payne, J: Pre- and post-vaccination lymphocyte stimulation with HBsAg in patients with anti-HBs alone. Hepatology 4:1079, 1984.
15. Bardawil, L, Kessler, H, **Jensen, D**, Payne, J, and Harris, A: Anti-HBs alone: IgM anti-HBs response to vaccination. Hepatology 4:1079, 1984.
16. **Jensen, DM**, Kessler, H, Maley, M, and Payne, J: Concomitant acute viral hepatitis B and delta hepatitis. Gastroenterology 88:1667, 1985.
17. Schaffner, J, Royse, V, Maley, M, Linderman, M, and **Jensen, D**: Characterization of amylase isoenzymes after cardiopulmonary bypass (CPB) using agarose gel electrophoresis. Gastroenterology 88:1572, 1985.
18. **Jensen, D**, Linderman, M, and Maley, M: The relationship between alanine aminotransferase (ALT) levels and the prevalence of serologic markers for hepatitis A, B, and delta in an outpatient population. Hepatitis Scientific Memoranda 8:110-111, 1985.
19. Benson, C, Kessler, H, Harris, A, Borough, Y, Kapell, K, **Jensen, D**: Immunogenicity and reactogenicity of two lots of recombinant hepatitis B vaccine of different potency. J Clin Micro 1986.
20. **Jensen, DM**, Linderman, M, Dickerson, DD, Kessler, HA: Alanine aminotransferase (ALT) levels and prevalence of hepatitis A, B, and delta serologic markers in an outpatient population. Hepatology 6:1132, 1986.
21. **Jensen, DM**, Royse, VL, Glonek, T, Sabesin, S: Alterations in rat liver high energy phosphate metabolism during warm ischemia: correlation of ³¹P NMR with electron microscopy. Hepatology 6:1195, 1986.

22. Deziel D, **Jensen DM**, Faibisoff J, Silver A, Sabesin S: Pancreatic and biliary complications following extracorporeal gallstone lithotripsy. Am Surg, March 1991, p. 194.
23. **Jensen DM**, Deziel D, Faibisoff J, Silver A, and Sabesin S: Fragmentation of large and multiple gallstones using the EDAP LT-01 piezoelectric lithotripter. Gastroenterology 98:A595, 1990
24. **Jensen DM**, Deziel DJ, Faibisoff J, Silver A, Sabesin S: Successful fragmentation of large and small gallstones using the EDAP LT-01 piezoelectric lithotripter. J. Lithotripsy & Stone Dis 2:246, 1990.
25. Treadwell TL, Keefee EB, Lake JR, Read A, Friedman L, Goldman IS, Howell CD, deMedina M, Schiff ER, **Jensen DM**, Moonsammy G and Boscia JA: Immunogenicity of two recombinant hepatitis B vaccines in older individuals. Gastroenterology, 102:A903, 1992.
26. Yanacek D, **Jensen DM**, Rosenblate H, Silver A, Keith R, and Sabesin S: Interferon treatment of chronic hepatitis C: Frequency of dosage reductions during the course of therapy. Gastroenterology, 102:A912, 1992.
27. Ganger D, Matalon T, **Jensen DM**, Patel S, Brunner M, Rosenblate H, Siliunas D: Transjugular intrahepatic portosystemic shunt (TIPS): efficacy and complications. A learning experience. Gastroenterology, 1992.
28. Podila PV, **Jensen DM**, Ganger D, Rosenblate H & Coy D: Comparison of interferon alfa-2b in cirrhotic and non-cirrhotic patients with hepatitis C. Gastroenterology 1993;104:A973.
29. **Jensen DM**, Pothamsetty S, Ganger D, Rosenblate H, Coy D, and Soble J: Clinical manifestations of cirrhotic patients with intrapulmonary shunts. Gastroenterology. 106:A912, 1994.
30. Ganger DR, Matalon T, **Jensen DM**, Coy DL, Rosenblate H, Forouzandeh B: TIPS in non-liver transplant candidates: is it indicated? Gastroenterology 106:A896, 1994.
31. Kures PR, Soble JS, Neumann AS, **Jensen DM**, Pekofske A, Liebson PR, Parillo JE: Frequency of intrapulmonary to left heart shunt detected by contrast echocardiography in advanced liver disease. J Am Soc Echo 7:S63, 1994.
32. Spiess SE, Ganger DG, Matalon TA, **Jensen DM**, Rosenblate H: The role of TIPS in non-liver transplant candidates. Midwest Practice Management Conference for Gastroenterology Fellows, Chicago, IL, Dec 9-10, 1994
33. Mukunda R, Kane S, Foster P, McChesney L, Sankary H, Williams J, **Jensen DM**, Rosenblate H, Koukoulis G, Ganger D: Liver transplantation for hepatocellular carcinoma. Hepatology 22:460A, 1995.
34. Lee WM and the **Hepatitis Study Group**: Does hepatitis C viral (HCV) genotype or initial HCV RNA titer predict induction of response to interferon alfa 2a in chronic hepatitis C? Hepatology 22:176A, 1995.
35. Tong MJ, Reddy KR, Lee WM, Pockros PJ, Hoefs JC, Keefe E, Hollinger FB, Hoethcote JL, White H, Foust RT, **Jensen DM**, Krawitt EL, Fromm H, Black M, Klein M, Lubina J, Manyak C, Blatt LM and the Consensus Interferon Study Group: A phase 3 study for the treatment of patients with chronic hepatitis C (HCV) infection with consensus interferon. Gastroenterology (submitted) 1996
36. Reddy KR, Blatt LM, Conrad A, and the **Consensus Interferon Study Group**: Genotype distribution in 815 chronic HCV infected patients in North America. Gastroenterology 110:A1303, 1996
37. JC Gochu. **DM Jensen**, S Kaur, D Ganger, H Rosenblate: Prevalence of hepatitis C antibody positivity among spouses of liver transplant recipients with hepatitis C infection. Gastroenterology 110:A1198, 1996.
38. Hollinger FB, Blatt LM, Tong MJ, and the **Consensus Interferon Study Group**: Differential response to treatment with consensus interferon and IFN-a 2b in chronic HCV patients infected with genotype 1b. Gastroenterology 110:A1213 1996.
39. Craig JR, Bain VG, Black M and the **Consensus Interferon Study Group**: Liver histology improvement is associated with ALT and HCV RNA response following treatment with consensus interferon (CIFN). Gastroenterology 110:A1175,1996.

40. Hollinger FB, Tong MJ, Reddy KR, Lee WM, Pockros PJ, Hoefs JC, Keeffe E, Heathcote J, White H, Foust RT, **Jensen DM**, Krawitt E, Fromm H, Black M, Klein M, Lubina J, Manyak C, Blatt LM: A phase 3 study for the treatment of patients with chronic hepatitis C (HCV) infection with consensus interferon (CIFN). Triennial Hepatitis Meeting, Rome, April, 1996.
41. Sabesin SM, Brosgol FL, Earnest DL, Henderson MD, **Jensen DM**, Markello R, Orland BI, Peterson WL, Spiro AH, and Toskes PP: Results of a GI disease self-assessment test to evaluate primary care proficiency in managed care settings. Gastroenterology 110:A36 1996.
42. EL Krawitt, LM Blatt, MJ Tong, WM Lee, K Mullen, JC Hoefs, E Keeffe, FB Hollinger, H White, RT Foust, **DM Jensen**, H Fromm, M Black, D Albert, T Gerrard, and the Consensus Interferon Study Group: Biochemical and virological response to consensus interferon (CIFN) in low viral titer chronic HCV patients. Hepatology (submitted) 1996.
43. **DM Jensen**, LM Blatt, MJ Tong, WM Lee, K Mullen, JC Hoefs, E Keeffe, FB Hollinger, E JL Heathcote, H White, RT Foust, H Fromm, M Black, D Albert, T Gerrard, and the Consensus Interferon Study Group: Treatment of high viral titer chronic HCV patients with consensus interferon (CIFN) results in a significantly greater number of sustained HCV RNA responders compared to treatment with interferon α -2b. Hepatology 24:A275, 1996.
44. JC Gochu , A Mirza, S Kaur, D Ganger, H Rosenblate, **DM Jensen**: The effect of interferon therapy on alpha-fetoprotein levels. Hepatology 24:A397, 1996.
45. J Gochu, S Cotler, S Kaur, G Koukoulis, D Ganger, H Rosenblate, **DM Jensen**: Cyclosporine monotherapy for preventing graft rejection in hepatitis B liver transplant recipients: a serologic and histologic analysis. Hepatology 24:A516 1996.
46. R Levy, T Matalon, V McDonald, H Rosenblate, **DM Jensen**, S Kaur, D Ganger: Transjugular intrahepatic portal systemic shunt: long term outcome in patients with refractory ascites. Hepatology 24:A537 1996.
47. K Venkat, W Farooqi, A Chawla, G Dawson, G Schlauder, S Kaur, J Gochu, D Ganger, H Rosenblate and **DM Jensen**: The prevalence of GBV-C virus in patients with chronic liver disease. Hepatology 24:A594, 1996.
48. D Rowell, S Nagy, G Koukoulis, S Cotler, **DM Jensen**, J Williams, S Kaur: An elevated rejection activity index (RAI Banff Scheme) within 8 weeks after liver transplantation is associated with graft loss or liver-related death at 2 years. Gastroenterology (DDW) 1997.
49. D Rowell, **DM Jensen**, G Koukoulis, E Fagan, S Kaur, J Williams, S Cotler: Cumulative corticosteroid dose during the first month after liver transplantation (OLT) is associated with progressive hepatitis C - related histologic injury one year post-transplant. Gastroenterology (DDW), 1997.
50. S. Cotler, D Albert, H Rosenblate, D Ganger, **DM Jensen**: Interferon therapy for chronic hepatitis C is associated with sustained histologic improvement in virological nonresponders and responders with relapse (RR). J. Hepatology (EASL), 1997.
51. **DM Jensen**, D Shafritz, J Craig, E Krawitt, and the CIFN Study Group: Nonresponders to CIFN show clinically relevant improvements in liver histology. Gastroenterology (DDW), 1997.
52. Wood N, Jakate S, Cotler S, Rowell D, Kaur S, Koukoulis G, **Jensen DM**, Fagan E: High liver HCV RNA levels with early centrilobular and bile duct injury predict progressive graft damage. Hepatology (AASLD) 1998.
53. Everson GT, **Jensen DM**, Craig JR, et al: Efficacy of interferon treatment for patients with chronic hepatitis C: comparison of response in cirrhotics, fibrotics, or nonfibrotics. Hepatology (AASLD), 1998.
54. **Jensen DM**, Ganger DR, Cotler SJ, Vance M, Doyle L, Ulleweit B, Havlin D: Herbal and vitamin/mineral supplement use during antiviral therapy for hepatitis C. Hepatology (AASLD), 1999;30:193A.
55. **Jensen DM**, Merel N, Cotler SJ, Gochu J, Ganger D, Kaur S, Rosenblate H: Determinants of an elevated alpha-fetoprotein (AFP) level in patients with chronic hepatitis C: Effect of interferon therapy. Hepatology (AASLD) 1999; 30:205A

56. Cotler S, Ganger D, Kaur S, Rosenblate H, Jakate S, Sullivan D, Gretch D, **Jensen DM**: Daily interferon therapy for the treatment of hepatitis C infection in liver transplant recipients. Hepatology (AASLD) 1999; 30:246A.
57. Cotler S, Ganger D, Rosenblate H, Silver A, **Jensen DM**: Single dose pharmacodynamics of interferon alfacon-1 in nonresponder patients with chronic hepatitis C virus (HCV) infection. Hepatology (AASLD) 1999; 30:262A.
58. Fontana R, Keeffe E, Han S, Wright T, Davis G, Lilly L, Carey W, Fried M, **Jensen DM**, Luketic V, Kowdley K, Lok ASF: Prevention of recurrent hepatitis B infection following liver transplantation: Experience in 112 North American patients. Hepatology (AASLD) 1999; 30:301A.
59. Angtuaco T, Ngui SL, Ganger D, Cotler S, Kaur S, **Jensen DM**: High prevalence of 1762t 1764a mutations in the core promoter of hepatitis B virus (HBV) in patients with HBV-related end-stage liver disease. Hepatology (AASLD) 1999; 30:638A.
60. **Jensen DM**, Cotler S, Harb G, Poulios N, Shillington A, Hassan E, Vance M: Comparison of outcomes, treatment selection and completion in hepatitis C patients in academic and community based ambulatory treatment centers. Hepatology (AASLD) 2001; 34:422A.
61. Hadziyannis S, Cheinquer H, Morgan T, Diago M, **Jensen DM**, Ribas E, Bodenheimer H, Zarski J, Lee S, Roberts P, Ackrill A: Prospective evaluation of early virological response associated with 40 kDa peginterferon alfa-2A (Pegasys) plus ribavirin therapy from a phase III, randomized, double-blind study examining the effects of treatment duration and ribavirin dosing. Hepatology (AASLD) 2001; 34:328A.
62. Ferenci P, Shiffman M, Fried M, Sulkowski M, Haeussinger D, Zarski J, **Jensen DM**, Bonino F, Dhumeaux D, Blotner S, Hoffman J, Oliveto J: early prediction of response to 40 kDa peginterferon alfa-2A (Pegasys) plus ribavirin in patients with chronic hepatitis C (CHC). Hepatology (AASLD) 2001; 34:351A.
63. Cotler S, Wiley T, Layden T, **Jensen DM**: A pilot study of the combination of cyclosporine A and interferon alfacon-1 for the treatment of hepatitis C in previous nonresponder patients. Hepatology (AASLD) 2001; 34:587A.
64. S D. Sullivan. **D M. Jensen**, D E. Bernstein, T I. Hassanein, G R. Foster, S S. Lee,; H Cheinquer, A Craxi, W Klaskala, K Pettit, K K. Patel, J Green: Cost-effectiveness of peginterferon alfa-2a (PEGASYS®) and ribavirin (COPEGUS®) compared with interferon alfa-2b and ribavirin for patients with chronic hepatitis C (CHC). Gastroenterology (DDW) 2004;
65. Attar B, Chinga-Alayo E, Pandolfi G, Adeyemi O, Cotler S, **Jensen D** and Reilly B: Factors implicated in receiving therapy in patients with hepatitis C ± HIV co-infection in a lower socio-economic group. ACG Annual Meeting. Abstract P328, p.48, 2004.
66. Dickson RC, Terrault N, Ishitani M, Reddy R, Sheiner P, Soldevila-Pico C, Luketic V, Brundage R, **Jensen DM**, Fried M, Brown R, Muenz L, Horwith G, Lok, A: The effect of hepatitis B replication status on hepatitis B immunoglobulin dose requirements and pharmacokinetics in liver transplantation for hepatitis B virus. Hepatology 2004;40:190A
67. Melson J, Morrissey M, Reau N, Cohen SM, Wiley-Lucas T, **Jensen DM**: Histologic, biochemical and genotypic markers as determinants of elevated alpha-fetoprotein in hepatitis C independent of hepatocellular carcinoma. Hepatology 2004;40:410A.
68. Swain M, Foster GR, Fried M, Hadziyannis S, Heathcote E, Jensen DM, Lee S, Pockros P, Sulkowski M, Trepo C: Clustering of poor prognostic factors in patients with hepatitis C. J Hepatol 2005;42:222.
69. Cohen SM, Sotil E, Woon S, Savo A, Reau N, **Jensen DM**, Wiley-Lucas T, Dodson F: Liver transplantation in severely obese patients: a single center experience. ACG 2005 (accepted)
70. **Jensen DM**, Marcellin P, et al: Rapid virological response at week 4 (RVR) of peginterferon alfa-2a (40 KD) (Pegasys) plus ribavirin treatment predicts a sustained virological response (SVR) after 24 weeks in genotype 1 patients. Hepatology 2005; (accepted)
71. Troy T, Hart J, **Jensen DM**, Mohanty S: Racial and ethnic variations in biopsy-proven non-alcoholic fatty liver disease (NAFLD). Hepatology 2005;42:618A.

72. Marcellin P, Freilich B, Andreone P, Brandao-Mello C, DiBisceglie A, Rai R, **Jensen DM**: Interim safety analysis of patients in the randomized, international retreatment with Pegasys in patients not responding to prior peginterferon alfa-2b/ribavirin (RBV) combination therapy (REPEAT). Hepatology 2005;42:657A.
73. Swain M, Foster GR, Hadziyannis S, Heathcote E, **Jensen DM**, Lee S, Pockros P, Sulkowski M, Trepo C: Clustering of poor prognostic factors in heavier patients with chronic hepatitis C (CHC): Baseline characteristics and outcomes with peginterferon alfa-2a (40 KD)(Pegasys) plus ribavirin (RBV, Copegus) in randomized, international, phase III trials. Hepatology 2005;42:687A.
74. Marcellin P and **Jensen DM**: Retreatment with Pegasys in patients not responding to prior peginterferon alfa-2b/ribavirin (RBV) combination therapy – efficacy analysis of the 12 week inductions period of the REPEAT study. Hepatology 2005;42:77A.
75. **Jensen DM**, Andreone P, Benhamou Y, Horsmans Y, Diago M, Martin A, Teuber G, Marcellin P: Safety of peginterferon alfa-2a (40kd) (PEGASYS®) (peg-ifn-2a [40kd]) plus ribavirin (Copegus®) among pegylated interferon alfa-2b (12kd)/ribavirin non-responders: Interim analysis of the REPEAT study. J Hepatology 2006;44:S216
76. Gitlin N, DiBisceglie A, Marcellin P, Bonkovsky H, Rai R, Rizzetto M, Teuber G, **Jensen DM**: Peginterferon alfa-2a (40kd) (peg-ifn α -2a) (PEGASYS®) plus ribavirin (rbv) (Copegus®) in pegylated interferon alfa-2b (12kd)/ribavirin non-responders with cirrhosis/advanced fibrosis: interim analysis of the REPEAT study. J Hepatol 2006;44:S213
77. Marcellin P and **Jensen DM**: Efficacy of standard-dose and fixed-dose induction peginterferon alpha-2a (40 kd) (Pegasys) plus ribavirin (Copegus) among pegylated interferon alpha-2b (12 kd)/ribavirin non-responders: interim analysis of the REPEAT study. J Hepatol 2006;44:S7
78. Swain M, Foster GR, Hadziyannis S, Heathcote E, **Jensen DM**, Lee S, Pockros P, Sulkowski M, Reddy, R, Trepo C: Poor prognostic factors in heavier patients with chronic hepatitis C (CHC) result in less favourable outcome. J Hepatol 2006;44:S227
79. **Jensen DM**, DiBisceglie A, Gitlin N, Reddy KR, Feinman V, Arora S, Marcellin P: Peginterferon alfa-2a (40 kd)(PEGASYS)(peg-IFN α -2a[40 kd]) plus ribavirin (RBV)(Copegus) in pegylated interferon alfa-2b (12 kd)/ribavirin non-responders: week 12 efficacy and safety outcomes of the REPEAT study. Gastroenterology 2006; 130:A836
80. Troy T, O'Brien B, Huo D, Campbell L, Hart J, Reddy G, Reau N, Te H, **Jensen DM**, Mohanty S: African Americans with biopsy proven non-alcoholic fatty liver disease have serum lower ALT levels. Gastroenterology 2006;130:A821
81. Troy T, O'Brien B, Huo D, Campbell L, Hart J, Reddy G, Reau N, Te H, **Jensen DM**, Mohanty S: African Americans with biopsy proven non-alcoholic fatty liver disease have less advanced histopathology. Gastroenterology 2006;130:A823.
82. Gitlin N, DiBisceglie A, Marcellin P, Bonkovsky H, Rai R, Rizzetto M, Teuber G, **Jensen DM**: Peginterferon alfa-2a (40kd) (PEGASYS®) plus ribavirin (RBV) (Copegus®) in pegylated interferon alfa-2b (12kd)/ribavirin non-responders with cirrhosis/advanced fibrosis: interim analysis of the REPEAT study. Gastroenterology 2006;130:A838
83. Spangler C, Han S, Kwasny M, Cohen S, Reau N, **Jensen DM**: Early predictors of hemoglobin reduction during the first four weeks of peginterferon alpha-2a/ribavirin therapy during chronic hepatitis C. Gastroenterology 2006;130:A844.
84. Fried M, **Jensen DM**, Rodriguez-Torres, Nyburg L, et al: Improved sustained virological response with higher fixed doses of Peginterferon alfa-2a plus ribavirin in patients with "difficult to cure" characteristics. Hepatology 2006;44:314A.
85. **Jensen DM**, Reau N, Hadzyanis S, et al: Early predictors of anemia in patients with HCV genotype 1 treated with Peginterferon alfa-2a plus ribavirin 1000-1200 mg per day. Hepatology 2006;44:338A.
86. Everson G, Tong M, Jacobson I, **Jensen DM**, et al: Interim results from a randomized, double-blind, placebo-controlled phase 1B study in subjects with chronic hepatitis C after

- treatment with GI5005, a yeast-based HCV immunotherapy targeting NS3 and core proteins. Hepatology 2006;44:697A.
87. Reddy, KG. Reau N, Te H., Mohanty S, Satoskar R, DeVoss A, Wherity K, **Jensen DM**: Candidacy for hepatitis C clinical trials at a tertiary referral Center. Hepatology 2007;46:626A
 88. Marcellin P; **Jensen D**; Hadziyannis S; Ferenci P: Differentiation of early virologic response (EVR) into RVR, complete EVR (cEVR) and partial EVR (pEVR) allows for a more precise prediction of SVR in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) (PEGASYS®) and ribavirin (COPEGUS®). Hepatology 2007;46:818A
 89. Satoskar R; Aronsohn A; Te HS; Mohanty SR; Reddy KG; Reau N; **Jensen DM**: A Nationwide Survey of Attitudes Toward Liver Transplantation in Alcoholic Liver Disease. Hepatology 2007;46:488A
 90. Te HS, Reddy, KG. Reau N, Mohanty S, Satoskar R, **Jensen DM**: Combined liver-heart transplantation in the United States. Hepatology 2007;46:487A
 91. Rodriguez-Torres M, Sulkowski M, Chung RT, Hamzeh FM and **Jensen DM**: Association of pre-treatment and on-treatment factors with rapid virologic response in HCV genotype 1 infected patients treated with PEGIFNa-2a/RBV. Hepatology 2007;46:817A
 92. **Jensen DM** and Marcellin P: Pegylated interferon alfa-2a (40KD) plus ribavirin (RBV) in prior non-responders to pegylated interferon alfa-2b (12KD)/RBV: final efficacy and safety outcomes of the REPEAT study. Hepatology 2007;46:291A.
 93. Schiff, ER; Everson, GT; Tsai, N; Bzowej, NH; Gish, RG; McHutchison, J; Jacobson, IM; Tong, MJ; **Jensen, DM**; Lauer, GM.; Cruickshank, S; Ferraro, J; Haller, A; Duke, R; Rodell, T; Apelian, D: HCV Specific Cellular Immunity, RNA Reductions, and Normalization of ALT in Chronic HCV Subjects after Treatment with GI-5005, a Yeast-Based Immunotherapy Targeting NS3 and Core: A Randomized, Double-blind, Placebo Controlled Phase 1b Study. Hepatology 2007;46:816A
 94. Fried M, **Jensen DM**, et al: Randomized, multicenter trial of intensified regimens of peginterferon alfa-2a and ribavirin in HCV patients with poor prognostic factors. AASLD 2007
 95. Te HS, Dasgupta KA, Mohanty SR, Reau NS, Satoskar RS, Millis JM, Testa G, Reddy KG, **Jensen DM**.: Use of the Immune Function Assay (Immuknow®) To Assess Immunosuppression in Liver Transplant Recipients. ATC submission, 2008
 96. Aronsohn A, Thistlethwaite R, **Jensen DM**, Ross L: Are the attitudes and practices of hepatologists and transplant surgeons regarding living donor transplantation in alcoholics justified? DDW 2008
 97. Lee, Ye-Jin; **Jensen, Donald M.**; Te, Helen; Reau, Nancy; Reddy, Kapuluru G.; Satoskar, Rohit S.; Mishra, Poonam; Hart, John; Mohanty, Smruti R: Clinical and Liver Histological Differences in Patients with Nonalcoholic Fatty Liver Disease (NAFLD) with and without Diabetes Mellitus (DM). DDW 2008
 98. Marcellin P¹, Freilich B, Andreone P, DiBisceglie A, Eduardo Brandao C, Reddy KR, Craxi A, Oliveira A, Teuber G, Messinger D, Hooper G, Popescu M, **Jensen DM**: HCV RNA Status at Week 12 of Treatment with Peginterferon alfa-2a (PEGASYS®)/Ribavirin (COPEGUS®) Predicts SVR in Patients with Prior Non-Response to Pegylated Interferon alfa-2b/Ribavirin: Results from the REPEAT Study. EASL 2008
 99. **Jensen DM**, Freilich B, Andreone P, DiBisceglie A, Eduardo Brandao C, Reddy KR, Craxi A, Oliveira A, Teuber G, Messinger D, Hooper G, Popescu M, Tietz A, Marcellin P: Easy to Assess On-treatment Parameters Correlate with Degree of Virological Response after 12 Weeks of Treatment: Results from the REPEAT Study. EASL 2008.
 100. Lee y-L, **Jensen DM**, Te H, Reau N, Reddy KG, Satoskar R, Mishra P, Hart J, Mohanty S: Clinical and liver histological differences in patients with nonalcoholic fatty liver disease (NAFLD) with and without diabetes mellitus. Gastroenterology 2008;134:P-178
 101. Marcellin P, Freilich B, Andreone P, DiBegli A, Brandao-Mello C, Reddy K, Craxi A, Olveiro A, Teuber G, Messinger D, Hooper G, Popescu M, **Jensen DM**: Type of response to prior

- pegylated interferon alfa-2b(12KD)/RBV predicts subsequent response to retreatment with peginterferon alfa-2a(40KD)/RBV. Gastroenterology 2008;134:P-180.
102. Marcellin P, Freilich B, Andreone P, DiBegliè A, Brandao-Mello C, Reddy K, Craxi A, Olveiro A, Teuber G, Messinger D, Hooper G, Popescu M, **Jensen DM**: HCV-RNA status at week 12 of treatment with peginterferon alfa-2a/RBV predicts SVR in patients with prior nonresponse to pegylated interferon alfa-2b/RBV: Results from the REPEAT study. Gastroenterology 2008;134:P-180
 103. **Jensen DM**, Freilich B, Andreone P, DiBegliè A, Brandao-Mello C, Reddy K, Craxi A, Olveiro A, Teuber G, Messinger D, Hooper G, Popescu M, Marcellin P: Easy to assess on-treatment parameters correlate with degree of virological response after 12 weeks of treatment. Gastroenterology 2008;134:P-180
 104. Aronsohn A, Thistlewaite R, **Jensen DM**, Ross L: Is there justification for the attitudes and practices of hepatologists and transplant surgeons regarding transplantation in patients with alcoholic liver disease. Gastroenterology 2008;134:P-229
 105. Refined prediction of week 12 response and SVR based on the virological response at week 4 in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) (PEGASYS) and ribavirin (COPEGUS). AASLD 2008
 106. A 72-week treatment duration with peginterferon alfa-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) has a favorable risk:benefit ratio in non-responders to pegylated interferon alfa-2b (12KD) plus ribavirin: findings of the multinational REPEAT study. AASLD 2008
 107. Evaluation of Early Null-response (eNR) as a Predictor of Nonresponse to PEG RBV in Patients with HCV. AASLD 2008
 108. Discordance between serum tacrolimus and immunosuppression levels in orthotopic liver transplant (OLT) recipients. AASLD 2008
 109. Clinical Associations of Elevated Alpha-fetoprotein, Independent of Hepatocellular Carcinoma, In Differing Etiologies of Cirrhosis
 110. Impact of Metabolic Syndrome on the Progression of Non-alcoholic Fatty Liver Disease (NAFLD)
 111. Refractory Spontaneous Bacterial Peritonitis: A Retrospective Study of the University of Chicago Experience. EASL 2009
 112. **Jensen DM**, et al: High rates of early viral response, promising safety profile and lack of resistance-related breakthrough in HCV GT 1 patients treated with RG7128 plus PEGIFN alfa-2a (40KD)/RBV: Planned week 12 interim analysis from the PROPEL study. AASLD 2010. Hepatology 2010;52:81A
 113. Reau N, Choi C, Te H, Mohanty S, Aronsohn A, Reddy G, **Jensen DM**: Interferon is underutilized in hepatitis B (HBV) patients most likely to have a favorable outcome. AASLD 2010. Hepatology 2010;52:517A
 114. Choi C, Reau N, Te H, Mohanty S, Reddy G, **Jensen DM**: Liver biopsy changes the management of HBV in 48% of treatment naïve patients. AASLD 2010. Hepatology 2010;52:517A
 115. Reau N, Choi C, Te H, Mohanty S, Aronsohn A, Reddy G, **Jensen DM**: Physician preference drives choice of oral hepatitis B therapy. AASLD 2010. Hepatology 2010;52:544A
 116. Asselah T, Essioux L, Marcellin P, Fried M, **Jensen DM**, Germer S, Benayed R, Chu T, Tietz A, Cchin D, Shulman N, Thommes J, Laughlin M, Lopatin U: Differential association of a chromosome 19 single nucleotide polymorphism (SNP: rs12979860) to outcome (early virologic response/sustained virologic response EVR/SVR) in naïve vs retreated HCV pts treated with IFN-based therapies. AASLD 2010. Hepatology 2010;52:773A
 117. Brown J, Johnson S, **Jensen DM**, Fried M, Cummins CO, Paiva A, Carney B: Optimizing hepatitis C treatment in practice: an assessment of physician stage-of-change in practice improvement. AASLD 2010. Hepatology 2010;52:787A.
 118. Chung B, Rueter EE, Cotler S, **Jensen DM**, Guzman G, van Breemen R, Gann P: Retinoid/Carotenoid Depletion in Hepatitis C: Fibrosis Stage in Relation to Serum Biomarkers for Antioxidant Status, Insulin Resistance & Oxidative Stress. USCAP 2014.